PDS Biotechnology (PDSB) EBT (2014 - 2026)
PDS Biotechnology's (PDSB) quarterly EBT came in at -$7.6 million in Q4 2025, up 4.9% YoY from -$7.2 million in Q4 2024, and up 16.06% on a QoQ basis from -$9.0 million in Q3 2025.
PDS Biotechnology (PDSB) EBT (2014 - 2026) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of EBT data on file, last reported at -$7.6 million in Q4 2025.
- Quarterly EBT rose 4.9% year-over-year to -$7.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$35.7 million (up 7.31% YoY) and the FY2025 annual result came in at -$35.7 million, up 7.31% from the prior year.
- EBT grew to -$7.6 million in Q4 2025, from -$9.0 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$4.7 million in Q1 2021 to a low of -$19.1 million in Q4 2022.
- A 5-year average of -$9.5 million and a median of -$9.3 million in 2024 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT plunged 217.22% — and 2023, when it jumped 43.05%.
- Tracing PDSB's EBT over 5 years: stood at -$6.3 million in 2021, then slumped by 202.81% to -$19.1 million in 2022, then jumped by 43.05% to -$10.9 million in 2023, then gained by 27.03% to -$8.0 million in 2024, then grew by 4.9% to -$7.6 million in 2025.
- The last three EBT figures came in at -$7.6 million (Q4 2025), -$9.0 million (Q3 2025), and -$9.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | PDS Biotechnology | 11.58 Mn | 11.58 Mn | - | -9.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.75 Mn |
| Dec 31, 2025 | -7.56 Mn |
| Sep 30, 2025 | -9.01 Mn |
| Jun 30, 2025 | -9.43 Mn |
| Mar 31, 2025 | -9.66 Mn |
| Dec 31, 2024 | -7.95 Mn |
| Sep 30, 2024 | -10.73 Mn |
| Jun 30, 2024 | -9.20 Mn |
| Mar 31, 2024 | -10.60 Mn |
| Dec 31, 2023 | -10.90 Mn |
| Sep 30, 2023 | -10.85 Mn |
| Jun 30, 2023 | -12.94 Mn |
| Mar 31, 2023 | -9.66 Mn |
| Dec 31, 2022 | -19.14 Mn |
| Sep 30, 2022 | -7.42 Mn |
| Jun 30, 2022 | -7.02 Mn |
| Mar 31, 2022 | -14.92 Mn |
| Dec 31, 2021 | -6.32 Mn |
| Sep 30, 2021 | -6.96 Mn |
| Jun 30, 2021 | -5.11 Mn |